gosset abstracts Added 16 November 2026. Search conference abstracts across meetings. Needs CLI 0.5.27 or later.
Search about 1.5 million conference abstracts from the meetings Gosset covers: oncology (ASCO, ESMO, ESMO Asia, AACR, SABCS, WCLC, SITC), haematology (ASH, EHA), immunology and dermatology (EULAR, ACR, AAD, EADV), cardiometabolic (ADA, ESC, EASL, DDW), respiratory (ATS, ERS), neurology (AAN) and gene therapy (ASGCT). One row is one presentation (abstract, poster, oral or late-breaker) at one edition of a meeting.
Use it to answer questions like:
- Where has dostarlimab been presented, at any meeting?
- What did ASCO 2025 show in non-small cell lung cancer?
- Which abstracts report on trial NCT04784715?
gosset abstracts [SEARCH] [filters] [output flags]SEARCH (optional) is free text over the abstract.
Needs CLI 0.5.27 or later
gosset abstracts arrived in 0.5.27. Check with gosset version, and upgrade with:
pip install -U gossetAn older CLI answers invalid choice: 'abstracts'.
Filters
| Flag | Accepts | Example |
|---|---|---|
SEARCH | free text | gosset abstracts "overall survival" --conference "ESMO 2025" |
--drug | drug name or id. Matches abstracts from every meeting | --drug dostarlimab |
--disease | disease name or id. Includes narrower diseases | --disease "non-small cell lung cancer" |
--target | target name or id of the primary drug | --target HER2 |
--modality | modality name or id of the primary drug | --modality ADC |
--company | developer of the primary drug, name or id | --company AstraZeneca |
--conference | a meeting series (every edition), a list, or one edition | --conference ASCO · --conference ASCO,ESMO · --conference "ESMO 2025" |
--year | edition year, or a list | --year 2025 · --year 2024,2025 |
--nct | trial registry id(s) the abstract is linked to | --nct NCT04784715 |
--phase | furthest phase the primary drug has reached in any indication | --phase 3 |
--min-impact | minimum Gosset impact score, 0 to 10 | --min-impact 8 |
--annotation-level | annotated or link_only (see below) | --annotation-level annotated |
--since / --until | presentation date YYYY-MM-DD | --since 2025-10-01 |
Default sort: newest presentation first. You can also sort on impact, title and edition, for example --sort=-impact.
Three more filters have no flag of their own. Pass them with --where:
| Condition | Meaning |
|---|---|
--where trial_link_source=reported_in_abstract | with --nct: only abstracts that state the trial id themselves |
--where trial_link_source=adjudicated | with --nct: only links Gosset's trial matcher and a reviewer confirmed |
--where is_drug=false | presentations that are not about a drug (epidemiology, devices, basic science) |
--phase is the drug's phase, not the study's
--phase 3 finds abstracts whose primary drug has reached Phase 3 somewhere. A Phase 1 dose-escalation poster for that drug matches too. To find a particular study, use --nct or free text.
Examples
Every meeting that presented a drug
--drug searches across meetings. Narrow it with --conference or --year:
gosset abstracts --drug dostarlimab --conference ESMO --fields edition,title --tableedition title
--------- ------------------------------------------------------------
ESMO 2026 LBA46 - Niraparib and dostarlimab plus radiotherapy (RT) in
ESMO 2026 LBA87 - Clinical complete response with dostarlimab monother
ESMO 2026 3548TiP - PRODIGE 90 (PREDIR-NEOREC): Neoadjuvant dostarlima
ESMO 2026 1345TiP - RODEO: pReOperative dostarlimab and novel therapie
…
… showing 25 of 46 totalDrop --conference ESMO to get every meeting (gosset abstracts --drug dostarlimab). A drug search across all meetings can take longer than the other examples on this page.
One conference edition
gosset abstracts --conference ASCO --year 2025 --disease "non-small cell lung cancer" --limit 5 --table--conference "ASCO 2025" is the same as --conference ASCO --year 2025. A series name on its own (--conference ESMO) covers every edition, and a list (--conference ASCO,ESMO --year 2024,2025) covers each combination.
# HER2 abstracts at ESMO 2025
gosset abstracts --conference "ESMO 2025" --target HER2 --limit 5 \
--fields edition,title,drug,developers --tableedition title drug developers
--------- ------------------------------------------------------------ ---------------------- ---------------------------
ESMO 2025 536MO - SHR-A1811 plus pertuzumab in human epidermal growth trastuzumab rezetecan Jiangsu Hengrui Medicine
ESMO 2025 737MO - Trastuzumab deruxtecan (T-DXd) in patients (pts) wit trastuzumab deruxtecan Daiichi Sankyo, AstraZeneca
ESMO 2025 291O - DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan trastuzumab deruxtecan Daiichi Sankyo, AstraZeneca
…
… showing 5 of 95 totalAbstracts linked to a trial
gosset abstracts --nct NCT04784715 --fields edition,title,trial_ids --tableedition title trial_ids
-------------- ------------------------------------------------------------ ------------------------
ESMO 2026 LBA49 - A DESTINY-Breast09 (DB-)09 analysis of trastuzumab d NCT04784715
ASCO 2026 A DESTINY-Breast09 analysis of treatment duration and clinic NCT04784715
SABCS 2025 Abstract RF6-07: Trastuzumab deruxtecan (T-DXd) + pertuzumab NCT04784715
ESMO Asia 2025 88MO Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxa NCT04784715
ESMO 2025 LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs tax NCT04784715
ASCO 2025 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + NCT04784715
SABCS 2022 Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxt NCT04538742, NCT04784715That is the DESTINY-Breast09 trial followed from meeting to meeting. Most abstracts name no trial, so a trial search finds the ones that do.
How a trial link was made
Each link carries its source in trial_links:
gosset abstracts --nct NCT04784715 --limit 1 \
--fields abstract_id,edition,trial_ids,trial_links,impact,annotation_level[
{
"abstract_id": "6adf96cb6965e686e3ad0f3d",
"edition": "ESMO 2026",
"trial_ids": ["NCT04784715"],
"trial_links": [
{"trial_id": "NCT04784715", "trial_link_source": "reported_in_abstract"},
{"trial_id": "NCT04784715", "trial_link_source": "adjudicated"}
],
"impact": 8,
"annotation_level": "annotated"
}
]trial_link_source | Meaning |
|---|---|
reported_in_abstract | The abstract states the id itself, in its registration field or as the only id in the text |
adjudicated | Gosset's trial matcher proposed the link and a reviewer confirmed it |
A link with both sources appears once per source. To keep only the ids the abstracts print themselves:
gosset abstracts --nct NCT04784715 --where trial_link_source=reported_in_abstract \
--fields edition,title,trial_ids --tableedition title trial_ids
--------- ------------------------------------------------------------ -----------
ESMO 2026 LBA49 - A DESTINY-Breast09 (DB-)09 analysis of trastuzumab d NCT04784715
ASCO 2026 A DESTINY-Breast09 analysis of treatment duration and clinic NCT04784715Trial ids from registries that issue bare numbers are prefixed with the registry, for example tctr:4765.
Drug class, phase and impact
# KRAS G12C abstracts from 2025 whose drug has reached Phase 3
gosset abstracts --target "KRAS G12C" --phase 3 --year 2025 --limit 5 \
--fields edition,title,drug,latest_phase --tableedition title drug latest_phase
--------- ------------------------------------------------------------ ---------- ------------
ESMO 2025 1846MO - Intracranial efficacy of olomorasib, a second-gener olomorasib 3
ESMO 2025 927MO - Single-agent divarasib experience in patients with K divarasib 3
WCLC 2025 OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunoth olomorasib 3
…
… showing 5 of 15 total# PD-1 abstracts at ASCO 2025 with an impact score of 9 or more
gosset abstracts --target PD-1 --conference "ASCO 2025" --min-impact 9 --limit 5 \
--fields edition,title,drug,impact --tableedition title drug impact
--------- ------------------------------------------------------------ ------------- ------
ASCO 2025 Pembrolizumab plus nab-paclitaxel and platinum as first-line pembrolizumab 9
ASCO 2025 Node-sparing modified short-course radiotherapy combined wit tislelizumab 9
…
… showing 5 of 73 total# A company's abstracts at one meeting
gosset abstracts --company AstraZeneca --conference ESMO --year 2025 --limit 3 \
--fields edition,title,drug --tableFree text and dates
gosset abstracts "overall survival" --conference "ESMO 2025" --limit 3 --fields edition,title --table
gosset abstracts --conference ESMO --since 2025-10-01 --until 2025-10-31 --limit 3 --fields date,edition,title --tableFree text is fastest with a conference or year filter alongside it.
The whole set, as JSON
gosset abstracts --nct NCT04784715 --all --fields edition,title > db09_abstracts.json--all pages for you and returns one array (7 abstracts here). It refuses sets above 10,000 rows, so add filters first.
Annotated and link-only abstracts
Every abstract has an annotation_level:
| Value | What it means |
|---|---|
annotated | Fully annotated: drug, disease, target and developer are extracted from the abstract |
link_only | Back catalogue, mostly 2004 to 2024. Linked only to drugs, diseases and companies already in Gosset, so its links are thinner |
gosset abstracts --conference ASCO --year 2015 --annotation-level link_only --limit 3 \
--fields edition,title,drug,annotation_level --tableedition title drug annotation_level
--------- ------------------------------------------------------------ ----------- ----------------
ASCO 2015 Ibrutinib combined with bendamustine and rituximab (BR) in p ibrutinib link_only
ASCO 2015 Phase II study of daratumumab (DARA) monotherapy in patients daratumumab link_only
ASCO 2015 Primary results, NRG Oncology/NSABP B-35: A clinical trial o anastrozole link_only
… showing 3 of 4879 totalUse --annotation-level annotated when you count or compare, so older, thinner rows don't skew the result.
Useful fields
Run gosset schema abstracts for the full list of 33 fields. The ones you'll use most:
| Field | What it holds |
|---|---|
abstract_id | Stable Gosset id for the presentation |
conference, conference_year, edition | Meeting series, year, and both as one label (ASCO 2025) |
date | Presentation or publication date. Some meetings publish only their start date |
title, authors, affiliations, url, doi | As published by the meeting |
abstract_number, poster_number, session_type, session_title | Where it sat in the programme |
body | Full abstract text, where the meeting site publishes it |
trial_registration, trial_ids, trial_links | The registration statement as printed, and the linked trials |
drug, other_drugs, developers | Primary drug, other drugs named, developers of the primary drug |
diseases, targets, target_classes, modalities, modality_classes | What the abstract is about |
latest_phase | Furthest phase the primary drug has reached in any indication, today |
impact, impact_comment | Gosset impact score (0 to 10) for abstracts reporting clinical results, with a one-line reason |
endpoints, summary | Endpoints reported, and structured findings (population, key results) where available |
annotation_level | annotated or link_only |
--table shows date, edition, title, drug, developers and trial ids. Add --fields to pick your own columns.
Piping to jq
# Endpoints and the impact rationale for the latest DESTINY-Breast09 abstract
gosset abstracts --nct NCT04784715 --limit 1 --fields title,endpoints,impact_comment \
| jq '.[0] | {endpoints, impact_comment}'From Python
from gosset import GossetClient
client = GossetClient()
res = client.query(
"abstracts",
where={"and": [
{"field": "trial", "value": "NCT04784715"},
{"field": "trial_link_source", "value": "reported_in_abstract"},
]},
fields=["edition", "title", "trial_ids"],
)
print(res["total"], [r["edition"] for r in res["results"]])